Trial reportPloS one2013
Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men.
Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- The relationship between hemoglobin andPloS one · 2023Pooled it
- Performance-Enhancing Drugs in Healthy Athletes: An Umbrella Review of Systematic Reviews and Meta-analyses.Sports healthPooled it
- Hemolysis during and after 21 days of head-down-tilt bed rest.Physiological reports · 2017Trial
- Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial.Sports medicine (Auckland, N.Z.) · 2016Trial
- Erythropoiesis-Targeted Doping in Sports: From Improved Oxygen Transport to Cardiovascular Risk.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Metabolomic responses are more sensitive in muscle than serum following 28 days of arduous exercise with erythropoietin administration.Experimental physiology · 2026Article
- Recombinant Human Erythropoietin Effects on Well-Trained Athletes' Endurance Performance: A Systematic Review.Sports (Basel, Switzerland) · 2025Review
- Strenuous training combined with erythropoietin induces red cell volume expansion-mediated hypervolemia and alters systemic and skeletal muscle iron homeostasis.American journal of physiology. Regulatory, integrative and comparative physiology · 2024Article
- The treatment of chronic anemia in heart failure: a global approach.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Review
- Exogenous erythropoietin increases hematological status, fat oxidation, and aerobic performance in males following prolonged strenuous training.Physiological reports · 2024Article
- Ten years of collecting hematological athlete biological passport samples-perspectives from a National Anti-doping Organization.Frontiers in sports and active living · 2022Article
- Altitude and Erythropoietin: Comparative Evaluation of Their Impact on Key Parameters of the Athlete Biological Passport: A Review.Frontiers in sports and active living · 2022Review
- Transcriptomic Markers of Recombinant Human Erythropoietin Micro-Dosing in Thoroughbred Horses.Genes · 2021Article
- Influence of advanced shoe technology on the top 100 annual performances in men's marathon from 2015 to 2019.Scientific reports · 2021Article
- Cross-platform transcriptomic profiling of the response to recombinant human erythropoietin.Scientific reports · 2021Article
- An Abductive Inference Approach to Assess the Performance-Enhancing Effects of Drugs Included on the World Anti-Doping Agency Prohibited List.Sports medicine (Auckland, N.Z.) · 2021Review
- Recent Improvements in Marathon Run Times Are Likely Technological, Not Physiological.Sports medicine (Auckland, N.Z.) · 2021Article
- Age and Hydration of Competing Horses Influence the Outcome of Elite 160 km Endurance Rides.Frontiers in veterinary science · 2021Article
- The detection of trans gene fragments of hEPO in gene doping model mice by Taqman qPCR assay.PeerJ · 2020Article
- Social Policy and Cognitive Enhancement: Lessons from Chess.Neuroethics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledRecombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb(mass)) and maximal oxygen uptake (v O(2 max)). PURPOSE: This study defined the time course of changes in Hb(mass), v O(2 max) as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field.
methods19 trained men received rHuEpo injections of 50 IU•kg(-1) body mass every two days for 4 weeks. Hb(mass) was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. v O(2 max) and 3,000 m time trial performance were measured pre, post administration and at the end of the study.
resultsRelative to baseline, running performance significantly improved by ∼6% after administration (10:30±1:07 min:sec vs. 11:08±1:15 min:sec, p<0.001) and remained significantly enhanced by ∼3% 4 weeks after administration (10:46±1:13 min:sec, p<0.001), while v O(2 max) was also significantly increased post administration (60.7±5.8 mL•min(-1)•kg(-1) vs. 56.0±6.2 mL•min(-1)•kg(-1), p<0.001) and remained significantly increased 4 weeks after rHuEpo (58.0±5.6 mL•min(-1)•kg(-1), p = 0.021). Hb(mass) was significantly increased at the end of administration compared to baseline (15.2±1.5 g•kg(-1) vs. 12.7±1.2 g•kg(-1), p<0.001). The rate of decrease in Hb(mass) toward baseline values post rHuEpo was similar to that of the increase during administration (-0.53 g•kg(-1)•wk(-1), 95% confidence interval (CI) (-0.68, -0.38) vs. 0.54 g•kg(-1•)wk(-1), CI (0.46, 0.63)) but Hb(mass) was still significantly elevated 4 weeks after administration compared to baseline (13.7±1.1 g•kg(-1), p<0.001).
conclusionRunning performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated v O(2 max) and Hb(mass).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.